Neumora Therapeutics Files Q1 2025 10-Q

Ticker: NMRA · Form: 10-Q · Filed: May 12, 2025 · CIK: 1885522

Neumora Therapeutics, INC. 10-Q Filing Summary
FieldDetail
CompanyNeumora Therapeutics, INC. (NMRA)
Form Type10-Q
Filed DateMay 12, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, quarterly-report

TL;DR

Neumora's Q1 2025 10-Q is in. Check their cash and securities.

AI Summary

Neumora Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including marketable securities and cash equivalents. Key dates mentioned include the filing date of May 12, 2025, and the fiscal year end of December 31.

Why It Matters

This filing provides investors with an update on Neumora's financial health and asset holdings as of the first quarter of 2025.

Risk Assessment

Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The reporting period is for the quarter ended March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on May 12, 2025.

What was Neumora Therapeutics, Inc.'s former company name?

Neumora Therapeutics, Inc.'s former company name was RBNC Therapeutics, Inc.

When did the company change its name?

The company changed its name on September 29, 2021.

What is the company's fiscal year end?

The company's fiscal year ends on December 31.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Neumora Therapeutics, Inc. (NMRA).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing